Zosano Pharma Corp (NASDAQ:ZSAN) Given Consensus Rating of “Buy” by Brokerages

Share on StockTwits

Zosano Pharma Corp (NASDAQ:ZSAN) has received a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.67.

ZSAN has been the topic of several research reports. ValuEngine raised Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Zosano Pharma in a report on Monday, June 15th. BTIG Research reduced their price objective on Zosano Pharma from $16.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Maxim Group reaffirmed a “buy” rating on shares of Zosano Pharma in a report on Wednesday, May 20th. Finally, Zacks Investment Research raised Zosano Pharma from a “sell” rating to a “hold” rating in a research note on Saturday.

NASDAQ ZSAN traded up $0.00 during trading hours on Tuesday, reaching $0.82. 596,600 shares of the company’s stock were exchanged, compared to its average volume of 2,459,623. The firm has a fifty day moving average of $0.90 and a 200-day moving average of $0.94. Zosano Pharma has a one year low of $0.41 and a one year high of $3.54. The company has a current ratio of 0.93, a quick ratio of 0.93 and a debt-to-equity ratio of 0.23. The stock has a market cap of $44.18 million, a PE ratio of -0.45 and a beta of 2.73.

Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. As a group, research analysts forecast that Zosano Pharma will post -0.5 EPS for the current year.

Several hedge funds have recently bought and sold shares of ZSAN. UBS Group AG lifted its stake in shares of Zosano Pharma by 45.8% in the 1st quarter. UBS Group AG now owns 99,932 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 31,375 shares during the period. Oxford Asset Management LLP acquired a new position in shares of Zosano Pharma in the 4th quarter valued at $57,000. Ieq Capital LLC acquired a new stake in Zosano Pharma during the 4th quarter worth $79,000. Sabby Management LLC acquired a new stake in Zosano Pharma during the 1st quarter worth $114,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in Zosano Pharma during the 4th quarter worth $182,000. 17.05% of the stock is currently owned by institutional investors.

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

See Also: Why does a company issue an IPO?

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.